Evan J Peterson1, Anne B Reaves2, Jennifer L Smith3, Carrie S Oliphant4. 1. Clinical Pharmacy Specialist - Cardiology, Seton Healthcare Family, Austin, Texas. 2. Clinical Specialist - Ambulatory Care. 3. Clinical Specialist - Emergency Medicine. 4. Clinical Specialist - Cardiology/Anticoagulation, Methodist University Hospital, Memphis, Tennessee; [At the time of writing, Dr. Peterson was PGY-1 Pharmacy Resident, Methodist University Hospital, Memphis, Tennessee.].
Abstract
BACKGROUND: Guidelines recommend that all patients with atrial fibrillation and a history of ischemic stroke should receive an anticoagulant. Prior analyses show that warfarin is underutilized in most populations. OBJECTIVE: To examine the use of antithrombotic and anticoagulant therapy in patients with atrial fibrillation or flutter during the index hospitalization for acute, ischemic stroke. METHODS: Retrospective electronic medical record review of 200 patients treated at a tertiary care hospital with a primary ICD-9 code for ischemic stroke and a secondary ICD-9 code for atrial fibrillation or flutter. Exclusion criteria were active bleeding, pregnancy, age less than 18, pre-existing warfarin allergy, or dabigatran use. RESULTS: Fifty-two percent of patients received at least one dose of warfarin during the index hospitalization. There was no relationship between CHADS2 score and likelihood of receiving warfarin (P > .05). There was no significant difference in adverse event rate in patients receiving warfarin compared to those receiving aspirin (3.8% vs 9.1%; P = .14), but the rate of hemorrhagic transformation was lower in patients receiving warfarin (1% vs 7%; P = .03). The composite of hemorrhagic stroke or hemorrhagic transformation was significantly lower in patients receiving bridging therapy (0% vs 11%; P = .03). Sixteen patients were readmitted for stroke within 3 months of discharge. Ten were readmitted for ischemic stroke, 3 for hemorrhagic stroke or hemorrhagic transformation, and 3 for systemic bleeding. Ten patients (62.5%) were receiving warfarin at readmission, but only one of these patients had a therapeutic INR. CONCLUSIONS: Warfarin was underutilized as secondary stroke prophylaxis in these high-risk patients. Bridging therapy appeared to be safe and was not associated with an increase in adverse events.
BACKGROUND: Guidelines recommend that all patients with atrial fibrillation and a history of ischemic stroke should receive an anticoagulant. Prior analyses show that warfarin is underutilized in most populations. OBJECTIVE: To examine the use of antithrombotic and anticoagulant therapy in patients with atrial fibrillation or flutter during the index hospitalization for acute, ischemic stroke. METHODS: Retrospective electronic medical record review of 200 patients treated at a tertiary care hospital with a primary ICD-9 code for ischemic stroke and a secondary ICD-9 code for atrial fibrillation or flutter. Exclusion criteria were active bleeding, pregnancy, age less than 18, pre-existing warfarin allergy, or dabigatran use. RESULTS: Fifty-two percent of patients received at least one dose of warfarin during the index hospitalization. There was no relationship between CHADS2 score and likelihood of receiving warfarin (P > .05). There was no significant difference in adverse event rate in patients receiving warfarin compared to those receiving aspirin (3.8% vs 9.1%; P = .14), but the rate of hemorrhagic transformation was lower in patients receiving warfarin (1% vs 7%; P = .03). The composite of hemorrhagic stroke or hemorrhagic transformation was significantly lower in patients receiving bridging therapy (0% vs 11%; P = .03). Sixteen patients were readmitted for stroke within 3 months of discharge. Ten were readmitted for ischemic stroke, 3 for hemorrhagic stroke or hemorrhagic transformation, and 3 for systemic bleeding. Ten patients (62.5%) were receiving warfarin at readmission, but only one of these patients had a therapeutic INR. CONCLUSIONS: Warfarin was underutilized as secondary stroke prophylaxis in these high-risk patients. Bridging therapy appeared to be safe and was not associated with an increase in adverse events.
Authors: L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy Journal: J Am Coll Cardiol Date: 2011-02-14 Impact factor: 24.094
Authors: Valentin Fuster; Lars E Rydén; Davis S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; G Neal Kay; Jean-Yves Le Huezey; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; L Samuel Wann Journal: J Am Coll Cardiol Date: 2011-03-15 Impact factor: 24.094
Authors: S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf Journal: Lancet Date: 2006-06-10 Impact factor: 79.321
Authors: Brian F Gage; Carl van Walraven; Lesly Pearce; Robert G Hart; Peter J Koudstaal; B S P Boode; Palle Petersen Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Stuart J Connolly; Janice Pogue; Robert G Hart; Stefan H Hohnloser; Marc Pfeffer; Susan Chrolavicius; Salim Yusuf Journal: N Engl J Med Date: 2009-03-31 Impact factor: 91.245
Authors: Karen L Furie; Larry B Goldstein; Gregory W Albers; Pooja Khatri; Ron Neyens; Mintu P Turakhia; Tanya N Turan; Kathryn A Wood Journal: Stroke Date: 2012-08-02 Impact factor: 7.914